Clinical evaluation of immunosuppressive acidic protein in the serum of patients with locally advanced breast cancer during mohs paste treatment

Locally advanced breast cancer lesions often compromise the patient's quality of life (QOL). Mohs paste is a histopathological fixative containing zinc chloride as the main ingredient. It has been applied to perform chemosurgery on skin tumors. In recent years, this paste has reportedly been very effective for controlling various symptoms of skin metastases in inoperable advanced cancer, such as pungent odor and hemorrhage, in the field of palliative care. We evaluated the clinical significance of immunosuppressive acidic protein (IAP) and C-reactive protein (CRP) in the serum of patients with locally advanced breast cancer during Mohs paste treatment. The tryptophan (Trp)Aynurenine (Kyn) ratio measures IDO activity. Trp and Kyn were measured by high performance liquid chromatography (HPLC). We took serum samples from 3 locally advanced breast cancer cases, in the pre-Treatment phase, 2 times after the treatment phase, and 5 times after the treatment phase. Then, we measured IAP and CRP in these samples during Mohs paste treatment. Serum IAP values did not differ significantly between each of the phases; however, serum CRP values were decreased by Mohs paste treatment. These results suggested that Mohs paste treatment for locally advanced breast cancer lesions was useful for enhancing the patient QOL, without immunosuppression.